Skip to main content
Erschienen in: Neurotherapeutics 4/2020

01.10.2020 | Review

Sleep Issues in Parkinson’s Disease and Their Management

verfasst von: José Rafael P. Zuzuárregui, Emmanuel H. During

Erschienen in: Neurotherapeutics | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Parkinson’s disease (PD) is an alpha-synucleinopathy that leads to prominent motor symptoms including tremor, bradykinesia, and postural instability. Nonmotor symptoms including autonomic, neurocognitive, psychiatric symptoms, and sleep disturbances are also seen frequently in PD. The impact of PD on sleep is related to motor and nonmotor symptoms, in addition to the disruption of the pathways regulating sleep by central nervous system pathology. Rapid eye movement sleep behavior disorder is a parasomnia that can lead to self-injury and/or injury to partners at night. Restless legs syndrome is a subjective sensation of discomfort and urge to move the legs prior to falling asleep and can lead to insomnia and reduced sleep quality. Excessive daytime sleepiness is common in PD and exerts a negative impact on quality of life in addition to increasing the risk of falls. Obstructive sleep apnea is a breathing disorder during sleep that can cause frequent awakenings and excessive daytime sleepiness. Circadian rhythm dysfunction can lead to an advanced or delayed onset of sleep in patients and create disruption of normal sleep and wake times. All of these disorders are common in PD and can significantly reduce sleep quantity, sleep quality, or quality of life for patients and caretakers. Treatment approaches for each of these disorders are distinct and should be individualized to the patient. We review the literature regarding these common sleep issues encountered in PD and their treatment options.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR, Group NV. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease. Mov Disord. 2011;26:399–406.PubMedCrossRef Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR, Group NV. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease. Mov Disord. 2011;26:399–406.PubMedCrossRef
2.
Zurück zum Zitat Gómez-Esteban JC, Tijero B, Somme J, et al. Impact of psychiatric symptoms and sleep disorders on the quality of life of patients with Parkinson’s disease. J Neurol. 2011;258(3):494-9.PubMedCrossRef Gómez-Esteban JC, Tijero B, Somme J, et al. Impact of psychiatric symptoms and sleep disorders on the quality of life of patients with Parkinson’s disease. J Neurol. 2011;258(3):494-9.PubMedCrossRef
3.
Zurück zum Zitat Dhawan V, Healy DG, Pal S, Chaudhuri KR. Sleep-related problems of Parkinson’s disease. Age Ageing. 2006;35(3):220-8.PubMedCrossRef Dhawan V, Healy DG, Pal S, Chaudhuri KR. Sleep-related problems of Parkinson’s disease. Age Ageing. 2006;35(3):220-8.PubMedCrossRef
4.
Zurück zum Zitat Hurt CS, Rixon L, Chaudhuri KR, Moss-Morris R, Samuel M, Brown RG. Barriers to reporting non-motor symptoms to health-care providers in people with Parkinson’s. Parkinsonism Relat Disord. 2019;64:220-225.PubMedCrossRef Hurt CS, Rixon L, Chaudhuri KR, Moss-Morris R, Samuel M, Brown RG. Barriers to reporting non-motor symptoms to health-care providers in people with Parkinson’s. Parkinsonism Relat Disord. 2019;64:220-225.PubMedCrossRef
5.
Zurück zum Zitat Hermanowicz N, Jones SA, Hauser RA. Impact of non-motor symptoms in Parkinson’s disease: a PMDAlliance survey. Neuropsychiatr Dis Treat. 2019;15:2205-2212.PubMedPubMedCentralCrossRef Hermanowicz N, Jones SA, Hauser RA. Impact of non-motor symptoms in Parkinson’s disease: a PMDAlliance survey. Neuropsychiatr Dis Treat. 2019;15:2205-2212.PubMedPubMedCentralCrossRef
6.
Zurück zum Zitat Mantovani S, Smith SS, Gordon R, O’Sullivan JD. An overview of sleep and circadian dysfunction in Parkinson’s disease. J Sleep Res. 2018;27(3):e12673. Mantovani S, Smith SS, Gordon R, O’Sullivan JD. An overview of sleep and circadian dysfunction in Parkinson’s disease. J Sleep Res. 2018;27(3):e12673.
8.
Zurück zum Zitat Rolinski M, Szewczyk-Krolikowski K, Tomlinson PR, et al. REM sleep behaviour disorder is associated with worse quality of life and other non-motor features in early Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2014;85(5):560-6.PubMedCrossRef Rolinski M, Szewczyk-Krolikowski K, Tomlinson PR, et al. REM sleep behaviour disorder is associated with worse quality of life and other non-motor features in early Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2014;85(5):560-6.PubMedCrossRef
9.
Zurück zum Zitat Rijsman RM, Schoolderman LF, Rundervoort RS, Louter M. Restless legs syndrome in Parkinson’s disease. Parkinsonism Relat Disord. 2014;20 Suppl 1:S5-9.PubMedCrossRef Rijsman RM, Schoolderman LF, Rundervoort RS, Louter M. Restless legs syndrome in Parkinson’s disease. Parkinsonism Relat Disord. 2014;20 Suppl 1:S5-9.PubMedCrossRef
11.
Zurück zum Zitat Zhu K, van Hilten JJ, Marinus J. The course of insomnia in Parkinson’s disease. Parkinsonism Relat Disord. 2016; 33:51-57.PubMedCrossRef Zhu K, van Hilten JJ, Marinus J. The course of insomnia in Parkinson’s disease. Parkinsonism Relat Disord. 2016; 33:51-57.PubMedCrossRef
12.
Zurück zum Zitat Chaudhuri KR, Pal S, DiMarco A, et al. The Parkinson’s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson’s disease.J Neurol Neurosurg Psychiatry. 2002;73(6):629-35.PubMedPubMedCentralCrossRef Chaudhuri KR, Pal S, DiMarco A, et al. The Parkinson’s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson’s disease.J Neurol Neurosurg Psychiatry. 2002;73(6):629-35.PubMedPubMedCentralCrossRef
13.
Zurück zum Zitat Trenkwalder C, Kohnen R, Högl B, et al. Parkinson’s disease sleep scale--validation of the revised version PDSS-2. Mov Disord. 2011;26(4):644-52.PubMedCrossRef Trenkwalder C, Kohnen R, Högl B, et al. Parkinson’s disease sleep scale--validation of the revised version PDSS-2. Mov Disord. 2011;26(4):644-52.PubMedCrossRef
14.
Zurück zum Zitat Romenets SR, Wolfson C, Galatas C, et al. Validation of the non-motor symptoms questionnaire (NMS-Quest). Parkinsonism Relat Disord. 2012; 18(1):54-8.PubMedCrossRef Romenets SR, Wolfson C, Galatas C, et al. Validation of the non-motor symptoms questionnaire (NMS-Quest). Parkinsonism Relat Disord. 2012; 18(1):54-8.PubMedCrossRef
15.
Zurück zum Zitat Muntean ML, Benes H, Sixel-Döring F, et al. Clinically relevant cut-off values for the Parkinson’s Disease Sleep Scale-2 (PDSS-2): a validation study. Sleep Med. 2016;24:87-92.PubMedCrossRef Muntean ML, Benes H, Sixel-Döring F, et al. Clinically relevant cut-off values for the Parkinson’s Disease Sleep Scale-2 (PDSS-2): a validation study. Sleep Med. 2016;24:87-92.PubMedCrossRef
16.
Zurück zum Zitat Louter M, van Sloun RJ, Pevernagie DA, et al. Subjectively impaired bed mobility in Parkinson disease affects sleep efficiency. Sleep Med. 2013; 14(7):668-74.PubMedCrossRef Louter M, van Sloun RJ, Pevernagie DA, et al. Subjectively impaired bed mobility in Parkinson disease affects sleep efficiency. Sleep Med. 2013; 14(7):668-74.PubMedCrossRef
17.
Zurück zum Zitat Uchino K, Shiraishi M, Tanaka K, Akamatsu M, Hasegawa Y. Impact of inability to turn in bed assessed by a wearable three-axis accelerometer on patients with Parkinson’s disease. PLoS One. 2017;12(11):e0187616.PubMedPubMedCentralCrossRef Uchino K, Shiraishi M, Tanaka K, Akamatsu M, Hasegawa Y. Impact of inability to turn in bed assessed by a wearable three-axis accelerometer on patients with Parkinson’s disease. PLoS One. 2017;12(11):e0187616.PubMedPubMedCentralCrossRef
18.
Zurück zum Zitat Loddo G, Calandra-Buonaura G, Sambati L, et al. The Treatment of Sleep Disorders in Parkinson’s Disease: From Research to Clinical Practice. Front Neurol. 2017;8:42.PubMedPubMedCentralCrossRef Loddo G, Calandra-Buonaura G, Sambati L, et al. The Treatment of Sleep Disorders in Parkinson’s Disease: From Research to Clinical Practice. Front Neurol. 2017;8:42.PubMedPubMedCentralCrossRef
19.
Zurück zum Zitat Wailke S, Herzog J, Witt K, Deuschl G, Volkmann J. Effect of controlled-release levodopa on the microstructure of sleep in Parkinson’s disease. Eur J Neurol. 2011; 18(4):590-6.PubMedCrossRef Wailke S, Herzog J, Witt K, Deuschl G, Volkmann J. Effect of controlled-release levodopa on the microstructure of sleep in Parkinson’s disease. Eur J Neurol. 2011; 18(4):590-6.PubMedCrossRef
20.
Zurück zum Zitat Pierantozzi M, Placidi F, Liguori C, et al. Rotigotine may improve sleep architecture in Parkinson’s disease: a double-blind, randomized, placebo-controlled polysomnographic study. Sleep Med. 2016; 21:140-4.PubMedCrossRef Pierantozzi M, Placidi F, Liguori C, et al. Rotigotine may improve sleep architecture in Parkinson’s disease: a double-blind, randomized, placebo-controlled polysomnographic study. Sleep Med. 2016; 21:140-4.PubMedCrossRef
21.
Zurück zum Zitat Calandra-Buonaura G, Guaraldi P, Doria A, et al. Rotigotine Objectively Improves Sleep in Parkinson’s Disease: An Open-Label Pilot Study with Actigraphic Recording. Parkinsons Dis. 2016; 2016:3724148.PubMedPubMedCentral Calandra-Buonaura G, Guaraldi P, Doria A, et al. Rotigotine Objectively Improves Sleep in Parkinson’s Disease: An Open-Label Pilot Study with Actigraphic Recording. Parkinsons Dis. 2016; 2016:3724148.PubMedPubMedCentral
22.
Zurück zum Zitat Ray Chaudhuri K, Martinez-Martin P, Rolfe KA, et al. Improvements in nocturnal symptoms with ropinirole prolonged release in patients with advanced Parkinson’s disease. Eur J Neurol. 2012; 19(1):105-13.PubMedCrossRef Ray Chaudhuri K, Martinez-Martin P, Rolfe KA, et al. Improvements in nocturnal symptoms with ropinirole prolonged release in patients with advanced Parkinson’s disease. Eur J Neurol. 2012; 19(1):105-13.PubMedCrossRef
23.
Zurück zum Zitat Poewe WH, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol. 2007; 6(6):513-20.PubMedCrossRef Poewe WH, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol. 2007; 6(6):513-20.PubMedCrossRef
24.
Zurück zum Zitat Xiang W, Sun YQ, Teoh HC. Comparison of nocturnal symptoms in advanced Parkinson’s disease patients with sleep disturbances: pramipexole sustained release versus immediate release formulations. Drug Des Devel Ther. 2018;12:2017-2024.PubMedPubMedCentralCrossRef Xiang W, Sun YQ, Teoh HC. Comparison of nocturnal symptoms in advanced Parkinson’s disease patients with sleep disturbances: pramipexole sustained release versus immediate release formulations. Drug Des Devel Ther. 2018;12:2017-2024.PubMedPubMedCentralCrossRef
25.
Zurück zum Zitat Schettino C, Dato C, Capaldo G, Sampaolo S, Di Iorio G, Melone MA. Rasagiline for sleep disorders in patients with Parkinson’s disease: a prospective observational study. Neuropsychiatr Dis Treat. 2016 Sep 29;12:2497-2502.PubMedPubMedCentralCrossRef Schettino C, Dato C, Capaldo G, Sampaolo S, Di Iorio G, Melone MA. Rasagiline for sleep disorders in patients with Parkinson’s disease: a prospective observational study. Neuropsychiatr Dis Treat. 2016 Sep 29;12:2497-2502.PubMedPubMedCentralCrossRef
26.
Zurück zum Zitat Follett KA, Weaver FM, Stern M, et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson’s disease. N Engl J Med. 2010;362(22):2077-91.PubMedCrossRef Follett KA, Weaver FM, Stern M, et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson’s disease. N Engl J Med. 2010;362(22):2077-91.PubMedCrossRef
27.
Zurück zum Zitat Weaver FM, Follett K, Stern M, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA. 2009;301(1):63-73.PubMedPubMedCentralCrossRef Weaver FM, Follett K, Stern M, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA. 2009;301(1):63-73.PubMedPubMedCentralCrossRef
28.
Zurück zum Zitat Schuepbach WM, Rau J, Knudsen K, et al. Neurostimulation for Parkinson’s disease with early motor complications. N Engl J Med. 2013;368(7):610-22.PubMedCrossRef Schuepbach WM, Rau J, Knudsen K, et al. Neurostimulation for Parkinson’s disease with early motor complications. N Engl J Med. 2013;368(7):610-22.PubMedCrossRef
29.
Zurück zum Zitat Kurcova S, Bardon J, Vastik M, et al. Bilateral subthalamic deep brain stimulation initial impact on nonmotor and motor symptoms in Parkinson’s disease: An open prospective single institution study. Medicine (Baltimore). 2018;97(5):e9750.PubMedPubMedCentralCrossRef Kurcova S, Bardon J, Vastik M, et al. Bilateral subthalamic deep brain stimulation initial impact on nonmotor and motor symptoms in Parkinson’s disease: An open prospective single institution study. Medicine (Baltimore). 2018;97(5):e9750.PubMedPubMedCentralCrossRef
30.
Zurück zum Zitat Choi JH, Kim HJ, Lee JY, et al. Long-term effects of bilateral subthalamic nucleus stimulation on sleep in patients with Parkinson’s disease. PLoS One. 2019;14(8):e0221219.PubMedPubMedCentralCrossRef Choi JH, Kim HJ, Lee JY, et al. Long-term effects of bilateral subthalamic nucleus stimulation on sleep in patients with Parkinson’s disease. PLoS One. 2019;14(8):e0221219.PubMedPubMedCentralCrossRef
31.
Zurück zum Zitat Deli G, Aschermann Z, Ács P, et al. Bilateral Subthalamic Stimulation can Improve Sleep Quality in Parkinson’s Disease. J Parkinsons Dis. 2015;5(2):361-8.PubMedCrossRef Deli G, Aschermann Z, Ács P, et al. Bilateral Subthalamic Stimulation can Improve Sleep Quality in Parkinson’s Disease. J Parkinsons Dis. 2015;5(2):361-8.PubMedCrossRef
32.
Zurück zum Zitat Sharma VD, Sengupta S, Chitnis S, Amara AW. Deep Brain Stimulation and Sleep-Wake Disturbances in Parkinson Disease: A Review. Front Neurol. 2018;9:697.PubMedPubMedCentralCrossRef Sharma VD, Sengupta S, Chitnis S, Amara AW. Deep Brain Stimulation and Sleep-Wake Disturbances in Parkinson Disease: A Review. Front Neurol. 2018;9:697.PubMedPubMedCentralCrossRef
33.
Zurück zum Zitat Sakakibara R, Panicker J, Finazzi-Agro E, et al. A guideline for the management of bladder dysfunction in Parkinson’s disease and other gait disorders. Neurourol Urodyn. 2016; 35(5):551-63.PubMedCrossRef Sakakibara R, Panicker J, Finazzi-Agro E, et al. A guideline for the management of bladder dysfunction in Parkinson’s disease and other gait disorders. Neurourol Urodyn. 2016; 35(5):551-63.PubMedCrossRef
34.
Zurück zum Zitat Matsubara T, Suzuki K, Fujita H, et al. Autonomic Symptoms Correlate with Non-Autonomic Non-Motor Symptoms and Sleep Problems in Patients with Parkinson’s Disease. Eur Neurol. 2018;80(3-4):193-199.PubMedCrossRef Matsubara T, Suzuki K, Fujita H, et al. Autonomic Symptoms Correlate with Non-Autonomic Non-Motor Symptoms and Sleep Problems in Patients with Parkinson’s Disease. Eur Neurol. 2018;80(3-4):193-199.PubMedCrossRef
35.
Zurück zum Zitat Zesiewicz TA, Evatt M, Vaughan CP, et al. Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson’s disease. Parkinsonism Relat Disord. 2015;21(5):514-20.PubMedCrossRef Zesiewicz TA, Evatt M, Vaughan CP, et al. Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson’s disease. Parkinsonism Relat Disord. 2015;21(5):514-20.PubMedCrossRef
36.
Zurück zum Zitat Orme S, Morris V, Gibson W, Wagg A. Managing Urinary Incontinence in Patients with Dementia: Pharmacological Treatment Options and Considerations. Drugs Aging. 2015;32(7):559-67.PubMedCrossRef Orme S, Morris V, Gibson W, Wagg A. Managing Urinary Incontinence in Patients with Dementia: Pharmacological Treatment Options and Considerations. Drugs Aging. 2015;32(7):559-67.PubMedCrossRef
37.
Zurück zum Zitat Peyronnet B, Vurture G, Palma JA, et al. Mirabegron in patients with Parkinson disease and overactive bladder symptoms: A retrospective cohort. Parkinsonism Relat Disord. 2018;57:22-26.PubMedCrossRef Peyronnet B, Vurture G, Palma JA, et al. Mirabegron in patients with Parkinson disease and overactive bladder symptoms: A retrospective cohort. Parkinsonism Relat Disord. 2018;57:22-26.PubMedCrossRef
38.
39.
Zurück zum Zitat Butala A, Shepard M, Pontone G. Neuropsychiatric aspects of Parkinson disease psychopharmacology: Insights from circuit dynamics. Handb Clin Neurol. 2019;165:83-121.PubMedCrossRef Butala A, Shepard M, Pontone G. Neuropsychiatric aspects of Parkinson disease psychopharmacology: Insights from circuit dynamics. Handb Clin Neurol. 2019;165:83-121.PubMedCrossRef
40.
Zurück zum Zitat Rana AQ, Qureshi ARM, Shamli Oghli Y, et al. Decreased sleep quality in Parkinson’s patients is associated with higher anxiety and depression prevalence and severity, and correlates with pain intensity and quality. Neurol Res. 2018;40(8):696-701.PubMed Rana AQ, Qureshi ARM, Shamli Oghli Y, et al. Decreased sleep quality in Parkinson’s patients is associated with higher anxiety and depression prevalence and severity, and correlates with pain intensity and quality. Neurol Res. 2018;40(8):696-701.PubMed
41.
Zurück zum Zitat Rutten S, Vriend C, van der Werf YD, Berendse HW, Weintraub D, van den Heuvel OA. The bidirectional longitudinal relationship between insomnia, depression and anxiety in patients with early-stage, medication-naïve Parkinson’s disease. Parkinsonism Relat Disord. 2017;39:31-36.PubMedPubMedCentralCrossRef Rutten S, Vriend C, van der Werf YD, Berendse HW, Weintraub D, van den Heuvel OA. The bidirectional longitudinal relationship between insomnia, depression and anxiety in patients with early-stage, medication-naïve Parkinson’s disease. Parkinsonism Relat Disord. 2017;39:31-36.PubMedPubMedCentralCrossRef
42.
Zurück zum Zitat Palmeri R, Lo Buono V, Bonanno L, et al. Potential predictors of quality of life in Parkinson’s Disease: Sleep and mood disorders. J Clin Neurosci. 2019;70:113-117.PubMedCrossRef Palmeri R, Lo Buono V, Bonanno L, et al. Potential predictors of quality of life in Parkinson’s Disease: Sleep and mood disorders. J Clin Neurosci. 2019;70:113-117.PubMedCrossRef
43.
44.
Zurück zum Zitat Rios Romenets S, Creti L, Fichten C, et al. Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson’s disease -- a randomized study. Parkinsonism Relat Disord. 2013;19(7):670-5.PubMedCrossRef Rios Romenets S, Creti L, Fichten C, et al. Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson’s disease -- a randomized study. Parkinsonism Relat Disord. 2013;19(7):670-5.PubMedCrossRef
45.
Zurück zum Zitat Patel S, Ojo O, Genc G, et al. A Computerized Cognitive behavioral therapy Randomized, Controlled, pilot trial for insomnia in Parkinson Disease (ACCORD-PD). J Clin Mov Disord. 2017;4:16.PubMedPubMedCentralCrossRef Patel S, Ojo O, Genc G, et al. A Computerized Cognitive behavioral therapy Randomized, Controlled, pilot trial for insomnia in Parkinson Disease (ACCORD-PD). J Clin Mov Disord. 2017;4:16.PubMedPubMedCentralCrossRef
46.
Zurück zum Zitat Humbert M, Findley J, Hernandez-Con M, Chahine LM. Cognitive behavioral therapy for insomnia in Parkinson’s disease: a case series. NPJ Parkinsons Dis. 2017;3:25.PubMedPubMedCentralCrossRef Humbert M, Findley J, Hernandez-Con M, Chahine LM. Cognitive behavioral therapy for insomnia in Parkinson’s disease: a case series. NPJ Parkinsons Dis. 2017;3:25.PubMedPubMedCentralCrossRef
47.
Zurück zum Zitat Lebrun C, Gély-Nargeot MC, Rossignol A, Geny C, Bayard S. Efficacy of cognitive behavioral therapy for insomnia comorbid to Parkinson’s disease: A focus on psychological and daytime functioning with a single-case design with multiple baselines. J Clin Psychol. 2019 20. Lebrun C, Gély-Nargeot MC, Rossignol A, Geny C, Bayard S. Efficacy of cognitive behavioral therapy for insomnia comorbid to Parkinson’s disease: A focus on psychological and daytime functioning with a single-case design with multiple baselines. J Clin Psychol. 2019 20.
48.
Zurück zum Zitat Raymackers JM, Andrade M, Baey E, Vanneste M, Evrard F. Bright light therapy with a head-mounted device for anxiety, depression, sleepiness and fatigue in patients with Parkinson’s disease. Acta Neurol Belg. 2019;119(4):607-613.PubMedCrossRef Raymackers JM, Andrade M, Baey E, Vanneste M, Evrard F. Bright light therapy with a head-mounted device for anxiety, depression, sleepiness and fatigue in patients with Parkinson’s disease. Acta Neurol Belg. 2019;119(4):607-613.PubMedCrossRef
49.
Zurück zum Zitat Silva-Batista C, de Brito LC, Corcos DM, Roschel H, de Mello MT, Piemonte MEP, Tricoli V, Ugrinowitsch C. Resistance Training Improves Sleep Quality in Subjects With Moderate Parkinson’s Disease. J Strength Cond Res. 2017;31(8):2270-2277.PubMedCrossRef Silva-Batista C, de Brito LC, Corcos DM, Roschel H, de Mello MT, Piemonte MEP, Tricoli V, Ugrinowitsch C. Resistance Training Improves Sleep Quality in Subjects With Moderate Parkinson’s Disease. J Strength Cond Res. 2017;31(8):2270-2277.PubMedCrossRef
50.
Zurück zum Zitat Amara AW, Wood KH, Joop A, Memon RA, Pilkington J, Tuggle SC, Reams J, Barrett MJ, Edwards DA, Weltman AL, Hurt CP, Cutter G, Bamman MM. Randomized, Controlled Trial of Exercise on Objective and Subjective Sleep in Parkinson’s Disease. Mov Disord. 2020;35(6):947-958.PubMedCrossRef Amara AW, Wood KH, Joop A, Memon RA, Pilkington J, Tuggle SC, Reams J, Barrett MJ, Edwards DA, Weltman AL, Hurt CP, Cutter G, Bamman MM. Randomized, Controlled Trial of Exercise on Objective and Subjective Sleep in Parkinson’s Disease. Mov Disord. 2020;35(6):947-958.PubMedCrossRef
51.
Zurück zum Zitat Seppi K, Ray Chaudhuri K, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson’s disease-an evidence-based medicine review. Mov Disord. 2019;34(2):180-198.PubMedPubMedCentralCrossRef Seppi K, Ray Chaudhuri K, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson’s disease-an evidence-based medicine review. Mov Disord. 2019;34(2):180-198.PubMedPubMedCentralCrossRef
52.
Zurück zum Zitat McCarter SJ, St Louis EK, Sandness DJ, et al. Antidepressants Increase REM Sleep Muscle Tone in Patients with and without REM Sleep Behavior Disorder. Sleep. 2015;38(6):907-17.PubMedPubMedCentral McCarter SJ, St Louis EK, Sandness DJ, et al. Antidepressants Increase REM Sleep Muscle Tone in Patients with and without REM Sleep Behavior Disorder. Sleep. 2015;38(6):907-17.PubMedPubMedCentral
53.
Zurück zum Zitat Zhang X, Sun X, Wang J, Tang L, Xie A. Prevalence of rapid eye movement sleep behavior disorder (RBD) in Parkinson’s disease: a meta and meta-regression analysis. Neurol Sci. 2017;38(1):163-170.PubMedCrossRef Zhang X, Sun X, Wang J, Tang L, Xie A. Prevalence of rapid eye movement sleep behavior disorder (RBD) in Parkinson’s disease: a meta and meta-regression analysis. Neurol Sci. 2017;38(1):163-170.PubMedCrossRef
54.
Zurück zum Zitat de Gage Billioti S, Moride Y, Ducruet T, et al. Benzodiazepine use and risk of Alzheimer’s disease: case-control study. BMJ. 2014;349:g5205.CrossRef de Gage Billioti S, Moride Y, Ducruet T, et al. Benzodiazepine use and risk of Alzheimer’s disease: case-control study. BMJ. 2014;349:g5205.CrossRef
55.
Zurück zum Zitat Gooneratne NS, Vitiello MV. Sleep in older adults: normative changes, sleep disorders, and treatment options. Clin Geriatr Med. 2014;30(3):591-627.PubMedPubMedCentralCrossRef Gooneratne NS, Vitiello MV. Sleep in older adults: normative changes, sleep disorders, and treatment options. Clin Geriatr Med. 2014;30(3):591-627.PubMedPubMedCentralCrossRef
56.
Zurück zum Zitat By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2015;63(11):2227-46.CrossRef By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2015;63(11):2227-46.CrossRef
57.
Zurück zum Zitat Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD; Clinical Guidelines Committee of the American College of Physicians. Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2016;165(2):125-33.PubMedCrossRef Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD; Clinical Guidelines Committee of the American College of Physicians. Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2016;165(2):125-33.PubMedCrossRef
58.
Zurück zum Zitat Herring WJ, Connor KM, Snyder E, et al. Suvorexant in Elderly Patients with Insomnia: Pooled Analyses of Data from Phase III Randomized Controlled Clinical Trials. Am J Geriatr Psychiatry. 2017;25(7):791-802.PubMedCrossRef Herring WJ, Connor KM, Snyder E, et al. Suvorexant in Elderly Patients with Insomnia: Pooled Analyses of Data from Phase III Randomized Controlled Clinical Trials. Am J Geriatr Psychiatry. 2017;25(7):791-802.PubMedCrossRef
59.
Zurück zum Zitat Schenck CH, Bundlie SR, Ettinger MG, Mahowald MW. Chronic behavioral disorders of human REM sleep: a new category of parasomnia. Sleep. 1986;9(2):293-308.PubMedCrossRef Schenck CH, Bundlie SR, Ettinger MG, Mahowald MW. Chronic behavioral disorders of human REM sleep: a new category of parasomnia. Sleep. 1986;9(2):293-308.PubMedCrossRef
60.
Zurück zum Zitat Boeve BF. REM sleep behavior disorder: Updated review of the core features, the REM sleep behavior disorder-neurodegenerative disease association, evolving concepts, controversies, and future directions. Ann N Y Acad Sci. 2010;1184:15.PubMedPubMedCentralCrossRef Boeve BF. REM sleep behavior disorder: Updated review of the core features, the REM sleep behavior disorder-neurodegenerative disease association, evolving concepts, controversies, and future directions. Ann N Y Acad Sci. 2010;1184:15.PubMedPubMedCentralCrossRef
61.
Zurück zum Zitat Fernández-Arcos A, Iranzo A, Serradell M, Gaig C, Santamaria J. The Clinical Phenotype of Idiopathic Rapid Eye Movement Sleep Behavior Disorder at Presentation: A Study in 203 Consecutive Patients. Sleep. 2016;39(1):121-32.PubMedPubMedCentralCrossRef Fernández-Arcos A, Iranzo A, Serradell M, Gaig C, Santamaria J. The Clinical Phenotype of Idiopathic Rapid Eye Movement Sleep Behavior Disorder at Presentation: A Study in 203 Consecutive Patients. Sleep. 2016;39(1):121-32.PubMedPubMedCentralCrossRef
62.
Zurück zum Zitat Saper CB. The neurobiology of sleep. Continuum (Minneap Minn). 2013;19(1 Sleep Disorders):19-31. Saper CB. The neurobiology of sleep. Continuum (Minneap Minn). 2013;19(1 Sleep Disorders):19-31.
63.
Zurück zum Zitat Iranzo A. The REM sleep circuit and how its impairment leads to REM sleep behavior disorder. Cell Tissue Res. 2018 Jul;373(1):245-266.PubMedCrossRef Iranzo A. The REM sleep circuit and how its impairment leads to REM sleep behavior disorder. Cell Tissue Res. 2018 Jul;373(1):245-266.PubMedCrossRef
64.
Zurück zum Zitat Boeve BF, Dickson DW, Olson EJ, et al. Insights into REM sleep behavior disorder pathophysiology in brainstem-predominant Lewy body disease. Sleep Med. 2007;8(1):60-4.PubMedCrossRef Boeve BF, Dickson DW, Olson EJ, et al. Insights into REM sleep behavior disorder pathophysiology in brainstem-predominant Lewy body disease. Sleep Med. 2007;8(1):60-4.PubMedCrossRef
65.
Zurück zum Zitat Postuma RB, Adler CH, Dugger BN, et al. REM sleep behavior disorder and neuropathology in Parkinson’s disease. Mov Disord. 2015;30(10):1413PubMedCrossRef Postuma RB, Adler CH, Dugger BN, et al. REM sleep behavior disorder and neuropathology in Parkinson’s disease. Mov Disord. 2015;30(10):1413PubMedCrossRef
66.
Zurück zum Zitat Högl B, Stefani A, Videnovic A. Idiopathic REM sleep behaviour disorder and neurodegeneration - an update. Nat Rev Neurol. 2018;14(1):40-55.PubMedCrossRef Högl B, Stefani A, Videnovic A. Idiopathic REM sleep behaviour disorder and neurodegeneration - an update. Nat Rev Neurol. 2018;14(1):40-55.PubMedCrossRef
67.
Zurück zum Zitat Arnaldi D, Antelmi E, St Louis EK, Postuma RB, Arnulf I. Idiopathic REM sleep behavior disorder and neurodegenerative risk: To tell or not to tell to the patient? How to minimize the risk?. Sleep Med Rev. 2017;36:82-95.PubMedCrossRef Arnaldi D, Antelmi E, St Louis EK, Postuma RB, Arnulf I. Idiopathic REM sleep behavior disorder and neurodegenerative risk: To tell or not to tell to the patient? How to minimize the risk?. Sleep Med Rev. 2017;36:82-95.PubMedCrossRef
68.
Zurück zum Zitat Iranzo A, Fernández-Arcos A, Tolosa E, et al. Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: study in 174 patients. PLoS One. 2014;9(2):e89741.PubMedPubMedCentralCrossRef Iranzo A, Fernández-Arcos A, Tolosa E, et al. Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: study in 174 patients. PLoS One. 2014;9(2):e89741.PubMedPubMedCentralCrossRef
69.
Zurück zum Zitat Galbiati A, Verga L, Giora E, Zucconi M, Ferini-Strambi L. The risk of neurodegeneration in REM sleep behavior disorder: A systematic review and meta-analysis of longitudinal studies. Sleep Med Rev. 2019;43:37-46.PubMedCrossRef Galbiati A, Verga L, Giora E, Zucconi M, Ferini-Strambi L. The risk of neurodegeneration in REM sleep behavior disorder: A systematic review and meta-analysis of longitudinal studies. Sleep Med Rev. 2019;43:37-46.PubMedCrossRef
70.
Zurück zum Zitat Jung Y, St Louis EK Treatment of REM Sleep Behavior Disorder. Curr Treat Options Neurol. 2016;18(11):50.PubMedCrossRef Jung Y, St Louis EK Treatment of REM Sleep Behavior Disorder. Curr Treat Options Neurol. 2016;18(11):50.PubMedCrossRef
71.
Zurück zum Zitat Aurora RN, Zak RS, Maganti RK, et al. Best Practice Guide for the Treatment of REM Sleep Behavior Disorder (RBD). J Clin Sleep Med. 2010; 6(1): 85–95.PubMedPubMedCentralCrossRef Aurora RN, Zak RS, Maganti RK, et al. Best Practice Guide for the Treatment of REM Sleep Behavior Disorder (RBD). J Clin Sleep Med. 2010; 6(1): 85–95.PubMedPubMedCentralCrossRef
72.
Zurück zum Zitat Teman PT, Tippmann-Peikert M, Silber MH, Slocumb NL, Auger RR. Idiopathic rapid-eye-movement sleep disorder: associations with antidepressants, psychiatric diagnoses, and other factors, in relation to age of onset. Sleep Med. 2009;10(1):60-5.PubMedCrossRef Teman PT, Tippmann-Peikert M, Silber MH, Slocumb NL, Auger RR. Idiopathic rapid-eye-movement sleep disorder: associations with antidepressants, psychiatric diagnoses, and other factors, in relation to age of onset. Sleep Med. 2009;10(1):60-5.PubMedCrossRef
73.
Zurück zum Zitat Bugalho P, Mendonça M, Barbosa R, Salavisa M. The influence of sleep disordered breathing in REM sleep behavior disorder. Sleep Med. 2017;37:210-215.PubMedCrossRef Bugalho P, Mendonça M, Barbosa R, Salavisa M. The influence of sleep disordered breathing in REM sleep behavior disorder. Sleep Med. 2017;37:210-215.PubMedCrossRef
74.
Zurück zum Zitat Gabryelska A, Roguski A, Simpson G, Maschauer EL, Morrison I, Riha RL. Prevalence of obstructive sleep apnoea in REM behaviour disorder: response to continuous positive airway pressure therapy. Sleep Breath. 2018;22(3):825-830.PubMedCrossRef Gabryelska A, Roguski A, Simpson G, Maschauer EL, Morrison I, Riha RL. Prevalence of obstructive sleep apnoea in REM behaviour disorder: response to continuous positive airway pressure therapy. Sleep Breath. 2018;22(3):825-830.PubMedCrossRef
75.
Zurück zum Zitat Ferri R, Marelli S, Ferini-Strambi L, et al. An observational clinical and video-polysomnographic study of the effects of clonazepam in REM sleep behavior disorder. Sleep Med. 2013;14(1):24-9.PubMedCrossRef Ferri R, Marelli S, Ferini-Strambi L, et al. An observational clinical and video-polysomnographic study of the effects of clonazepam in REM sleep behavior disorder. Sleep Med. 2013;14(1):24-9.PubMedCrossRef
76.
Zurück zum Zitat Li SX, Lam SP, Zhang J, et al. A prospective, naturalistic follow-up study of treatment outcomes with clonazepam in rapid eye movement sleep behavior disorder. Sleep Med. 21 (2016) 114–120.PubMedCrossRef Li SX, Lam SP, Zhang J, et al. A prospective, naturalistic follow-up study of treatment outcomes with clonazepam in rapid eye movement sleep behavior disorder. Sleep Med. 21 (2016) 114–120.PubMedCrossRef
77.
Zurück zum Zitat Shin C, Park H, Lee WW, Kim HJ, Kim HJ, Jeon B. Clonazepam for probable REM sleep behavior disorder in Parkinson’s disease: A randomized placebo-controlled trial. J Neurol Sci. 2019;401:81-86.PubMedCrossRef Shin C, Park H, Lee WW, Kim HJ, Kim HJ, Jeon B. Clonazepam for probable REM sleep behavior disorder in Parkinson’s disease: A randomized placebo-controlled trial. J Neurol Sci. 2019;401:81-86.PubMedCrossRef
78.
Zurück zum Zitat Boeve BF, Silber MH, Ferman TJ. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med. 2003;4(4):281-4.PubMedCrossRef Boeve BF, Silber MH, Ferman TJ. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med. 2003;4(4):281-4.PubMedCrossRef
79.
Zurück zum Zitat Kunz D, Mahlberg R. A two-part, double-blind, placebo-controlled trial of exogens melatonin in REM sleep behaviour disorder. J Sleep Res. 2010;19(4):591-6.PubMedCrossRef Kunz D, Mahlberg R. A two-part, double-blind, placebo-controlled trial of exogens melatonin in REM sleep behaviour disorder. J Sleep Res. 2010;19(4):591-6.PubMedCrossRef
80.
Zurück zum Zitat McGrane IR, Leung JG, St Louis EK, Boeve BF. Melatonin therapy for REM sleep behavior disorder: a critical review of evidence. Sleep Med. 2015;16(1):19-26.PubMedCrossRef McGrane IR, Leung JG, St Louis EK, Boeve BF. Melatonin therapy for REM sleep behavior disorder: a critical review of evidence. Sleep Med. 2015;16(1):19-26.PubMedCrossRef
81.
Zurück zum Zitat Jun JS, Kim R, Byun JI, et al. Prolonged-release melatonin in patients with idiopathic REM sleep behavior disorder. Ann Clin Transl Neurol. 2019;6(4):716-722.PubMedPubMedCentralCrossRef Jun JS, Kim R, Byun JI, et al. Prolonged-release melatonin in patients with idiopathic REM sleep behavior disorder. Ann Clin Transl Neurol. 2019;6(4):716-722.PubMedPubMedCentralCrossRef
82.
Zurück zum Zitat Gilat M, Coeytaux Jackson A, Marshall NS, et al. Melatonin for Rapid Eye Movement Sleep Behavior Disorder in Parkinson’s Disease: A Randomised Controlled Trial. Mov Disord. 2019 31. Gilat M, Coeytaux Jackson A, Marshall NS, et al. Melatonin for Rapid Eye Movement Sleep Behavior Disorder in Parkinson’s Disease: A Randomised Controlled Trial. Mov Disord. 2019 31.
83.
Zurück zum Zitat Nomura T, Kawase S, Watanabe Y, Nakashima K. Use of ramelteon for the treatment of secondary REM sleep behavior disorder. Intern Med. 2013;52(18):2123-6.PubMedCrossRef Nomura T, Kawase S, Watanabe Y, Nakashima K. Use of ramelteon for the treatment of secondary REM sleep behavior disorder. Intern Med. 2013;52(18):2123-6.PubMedCrossRef
84.
Zurück zum Zitat Esaki Y, Kitajima T, Koike S, et al. An Open-Labeled Trial of Ramelteon in Idiopathic Rapid Eye Movement Sleep Behavior Disorder. J Clin Sleep Med. 2016;12(5):689-93.PubMedPubMedCentralCrossRef Esaki Y, Kitajima T, Koike S, et al. An Open-Labeled Trial of Ramelteon in Idiopathic Rapid Eye Movement Sleep Behavior Disorder. J Clin Sleep Med. 2016;12(5):689-93.PubMedPubMedCentralCrossRef
85.
Zurück zum Zitat Kotagal V, Albin RL, Müller ML, et al. Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease. Ann Neurol. 2012;71(4):560-8.PubMedPubMedCentralCrossRef Kotagal V, Albin RL, Müller ML, et al. Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease. Ann Neurol. 2012;71(4):560-8.PubMedPubMedCentralCrossRef
86.
Zurück zum Zitat Di Giacopo R, Fasano A, Quaranta D, Della Marca G, Bove F, Bentivoglio AR. Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson’s disease. Mov Disord. 2012;27(4):559-61.PubMedCrossRef Di Giacopo R, Fasano A, Quaranta D, Della Marca G, Bove F, Bentivoglio AR. Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson’s disease. Mov Disord. 2012;27(4):559-61.PubMedCrossRef
87.
Zurück zum Zitat Brunetti V, Losurdo A, Testani E, et al. Rivastigmine for refractory REM behavior disorder in mild cognitive impairment. Curr Alzheimer Res. 2014;11(3):267-73.PubMedCrossRef Brunetti V, Losurdo A, Testani E, et al. Rivastigmine for refractory REM behavior disorder in mild cognitive impairment. Curr Alzheimer Res. 2014;11(3):267-73.PubMedCrossRef
88.
Zurück zum Zitat Ringman JM, Simmons JH. Treatment of REM sleep behavior disorder with donepezil: a report of three cases. Neurology. 2000;55(6):870-1.PubMedCrossRef Ringman JM, Simmons JH. Treatment of REM sleep behavior disorder with donepezil: a report of three cases. Neurology. 2000;55(6):870-1.PubMedCrossRef
89.
Zurück zum Zitat Massironi G, Galluzzi S, Frisoni GB. Drug treatment of REM sleep behavior disorders in dementia with Lewy bodies. Int Psychogeriatr. 2003;15(4):377-83.PubMedCrossRef Massironi G, Galluzzi S, Frisoni GB. Drug treatment of REM sleep behavior disorders in dementia with Lewy bodies. Int Psychogeriatr. 2003;15(4):377-83.PubMedCrossRef
90.
Zurück zum Zitat Larsson V, Aarsland D, Ballard C, Minthon L, Londos E. The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson’s disease dementia. Int J Geriatr Psychiatry. 2010;25(10):1030-8.PubMedCrossRef Larsson V, Aarsland D, Ballard C, Minthon L, Londos E. The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson’s disease dementia. Int J Geriatr Psychiatry. 2010;25(10):1030-8.PubMedCrossRef
91.
Zurück zum Zitat Sasai T, Inoue Y, Matsuura M. Effectiveness of pramipexole, a dopamine agonist, on rapid eye movement sleep behavior disorder. Tohoku J Exp Med. 2012;226(3):177-81.PubMedCrossRef Sasai T, Inoue Y, Matsuura M. Effectiveness of pramipexole, a dopamine agonist, on rapid eye movement sleep behavior disorder. Tohoku J Exp Med. 2012;226(3):177-81.PubMedCrossRef
92.
Zurück zum Zitat Kumru H, Iranzo A, Carrasco E, et al. Lack of effects of pramipexole on REM sleep behavior disorder in Parkinson disease. Sleep. 2008;31(10):1418-21.PubMedPubMedCentral Kumru H, Iranzo A, Carrasco E, et al. Lack of effects of pramipexole on REM sleep behavior disorder in Parkinson disease. Sleep. 2008;31(10):1418-21.PubMedPubMedCentral
93.
Zurück zum Zitat Abenza Abildúa MJ, Miralles Martinez A, Arpa Gutiérrez FJ, et al. Conditions associated with REM sleep behaviour disorder: Description of a hospital series. Neurologia. 2017. Abenza Abildúa MJ, Miralles Martinez A, Arpa Gutiérrez FJ, et al. Conditions associated with REM sleep behaviour disorder: Description of a hospital series. Neurologia. 2017.
94.
Zurück zum Zitat Shneerson JM. Successful treatment of REM sleep behavior disorder with sodium oxybate. Clin Neuropharmacol. 2009;32(3):158-9.PubMedCrossRef Shneerson JM. Successful treatment of REM sleep behavior disorder with sodium oxybate. Clin Neuropharmacol. 2009;32(3):158-9.PubMedCrossRef
95.
Zurück zum Zitat Liebenthal J, Valerio J, Ruoff C, Mahowald M. A Case of Rapid Eye Movement Sleep Behavior Disorder in Parkinson Disease Treated With Sodium Oxybate. JAMA Neurol. 2016;73(1):126-7.PubMedCrossRef Liebenthal J, Valerio J, Ruoff C, Mahowald M. A Case of Rapid Eye Movement Sleep Behavior Disorder in Parkinson Disease Treated With Sodium Oxybate. JAMA Neurol. 2016;73(1):126-7.PubMedCrossRef
96.
Zurück zum Zitat Moghadam KK, Pizza F, Primavera A, Ferri R, Plazzi G. Sodium oxybate for idiopathic REM sleep behavior disorder: a report on two patients. Sleep Med. 2017;32:16-21.PubMedCrossRef Moghadam KK, Pizza F, Primavera A, Ferri R, Plazzi G. Sodium oxybate for idiopathic REM sleep behavior disorder: a report on two patients. Sleep Med. 2017;32:16-21.PubMedCrossRef
97.
Zurück zum Zitat Allen RP, Picchietti DL, Garcia-Borreguero D, et al. Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria--history, rationale, description, and significance. Sleep Med. 2014;15(8):860-73.PubMedCrossRef Allen RP, Picchietti DL, Garcia-Borreguero D, et al. Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria--history, rationale, description, and significance. Sleep Med. 2014;15(8):860-73.PubMedCrossRef
98.
Zurück zum Zitat Trenkwalder C, Allen R, Högl B, Paulus W, Winkelmann J. Restless legs syndrome associated with major diseases: A systematic review and new concept. Neurology. 2016 ;86(14):1336-43.PubMedPubMedCentralCrossRef Trenkwalder C, Allen R, Högl B, Paulus W, Winkelmann J. Restless legs syndrome associated with major diseases: A systematic review and new concept. Neurology. 2016 ;86(14):1336-43.PubMedPubMedCentralCrossRef
99.
Zurück zum Zitat Bhalsing K, Suresh K, Muthane UB, Pal PK. Prevalence and profile of Restless Legs Syndrome in Parkinson’s disease and other neurodegenerative disorders: a case-control study. Parkinsonism Relat Disord. 2013;19(4):426-30.PubMedCrossRef Bhalsing K, Suresh K, Muthane UB, Pal PK. Prevalence and profile of Restless Legs Syndrome in Parkinson’s disease and other neurodegenerative disorders: a case-control study. Parkinsonism Relat Disord. 2013;19(4):426-30.PubMedCrossRef
100.
Zurück zum Zitat Earley CJ, Connor JR, Beard JL, Malecki EA, Epstein DK, Allen RP. Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. Neurology. 2000;54(8):1698-700.PubMedCrossRef Earley CJ, Connor JR, Beard JL, Malecki EA, Epstein DK, Allen RP. Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. Neurology. 2000;54(8):1698-700.PubMedCrossRef
101.
Zurück zum Zitat Daubian-Nose P, Frank MK, Esteves AM. Sleep disorders: a review of the interface between restless legs syndrome and iron metabolism. Sleep Sci 2014;7:234–7.PubMedPubMedCentralCrossRef Daubian-Nose P, Frank MK, Esteves AM. Sleep disorders: a review of the interface between restless legs syndrome and iron metabolism. Sleep Sci 2014;7:234–7.PubMedPubMedCentralCrossRef
102.
Zurück zum Zitat Silber MH, Becker PM, Earley C, Garcia-Borreguero D, Ondo WG. Medical Advisory Board of the Willis-Ekbom Disease Foundation. Willis-Ekbom Disease Foundation revised consensus statement on the management of restless legs syndrome. Mayo Clin Proc 2013;88:977–86.PubMedCrossRef Silber MH, Becker PM, Earley C, Garcia-Borreguero D, Ondo WG. Medical Advisory Board of the Willis-Ekbom Disease Foundation. Willis-Ekbom Disease Foundation revised consensus statement on the management of restless legs syndrome. Mayo Clin Proc 2013;88:977–86.PubMedCrossRef
103.
Zurück zum Zitat Ondo WG. Common comorbidities and differential diagnosis of restless legs syndrome. J Clin Psychiatry 2014;75:e06.PubMedCrossRef Ondo WG. Common comorbidities and differential diagnosis of restless legs syndrome. J Clin Psychiatry 2014;75:e06.PubMedCrossRef
104.
Zurück zum Zitat Wong JC, Li Y, Schwarzschild MA, Ascherio A, Gao X. Restless legs syndrome: an early clinical feature of Parkinson disease in men. Sleep. 2014;37(2):369-72.PubMedPubMedCentralCrossRef Wong JC, Li Y, Schwarzschild MA, Ascherio A, Gao X. Restless legs syndrome: an early clinical feature of Parkinson disease in men. Sleep. 2014;37(2):369-72.PubMedPubMedCentralCrossRef
105.
Zurück zum Zitat Szatmari S Jr, Bereczki D, Fornadi K, Kalantar-Zadeh K, Kovesdy CP, Molnar MZ. Association of Restless Legs Syndrome With Incident Parkinson’s Disease. Sleep. 2017 1;40(2). Szatmari S Jr, Bereczki D, Fornadi K, Kalantar-Zadeh K, Kovesdy CP, Molnar MZ. Association of Restless Legs Syndrome With Incident Parkinson’s Disease. Sleep. 2017 1;40(2).
106.
Zurück zum Zitat Angelini M, Negrotti A, Marchesi E, Bonavina G, Calzetti S. A study of the prevalence of restless legs syndrome in previously untreated Parkinson’s disease patients: absence of co-morbid association. J Neurol Sci. 2011;310(1-2):286-8.PubMedCrossRef Angelini M, Negrotti A, Marchesi E, Bonavina G, Calzetti S. A study of the prevalence of restless legs syndrome in previously untreated Parkinson’s disease patients: absence of co-morbid association. J Neurol Sci. 2011;310(1-2):286-8.PubMedCrossRef
107.
Zurück zum Zitat Lee JE, Shin HW, Kim KS, Sohn YH. Factors contributing to the development of restless legs syndrome in patients with Parkinson disease. Mov Disord. 2009;24(4):579-82.PubMedCrossRef Lee JE, Shin HW, Kim KS, Sohn YH. Factors contributing to the development of restless legs syndrome in patients with Parkinson disease. Mov Disord. 2009;24(4):579-82.PubMedCrossRef
108.
Zurück zum Zitat Allen RP, Picchietti DL, Auerbach M, et al. Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children: an IRLSSG task force report. Sleep Med. 2018;41:27-44.PubMedCrossRef Allen RP, Picchietti DL, Auerbach M, et al. Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children: an IRLSSG task force report. Sleep Med. 2018;41:27-44.PubMedCrossRef
109.
Zurück zum Zitat Garcia-Borreguero D, Kohnen R, Silber MH, et al. The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group. Sleep Med 2013;14:675–84.PubMedCrossRef Garcia-Borreguero D, Kohnen R, Silber MH, et al. The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group. Sleep Med 2013;14:675–84.PubMedCrossRef
110.
Zurück zum Zitat De Cock Cochen V. Therapies for Restless Legs in Parkinson’s Disease. Curr Treat Options Neurol. 2019;21(11):56.CrossRef De Cock Cochen V. Therapies for Restless Legs in Parkinson’s Disease. Curr Treat Options Neurol. 2019;21(11):56.CrossRef
111.
Zurück zum Zitat Winkelman JW, Armstrong MJ, Allen RP, et al. Practice guideline summary: Treatment of restless legs syndrome in adults: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2016;87(24):2585-2593.PubMedPubMedCentralCrossRef Winkelman JW, Armstrong MJ, Allen RP, et al. Practice guideline summary: Treatment of restless legs syndrome in adults: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2016;87(24):2585-2593.PubMedPubMedCentralCrossRef
112.
Zurück zum Zitat Giorgi L, Asgharian A, Hunter B. Ropinirole in patients with restless legs syndrome and baseline IRLS total scores ≥ 24: efficacy and tolerability in a 26-week, double-blind, parallel-group, placebo-controlled study followed by a 40-week open-label extension. Clin Ther. 2013; 35(9):1321-36.PubMedCrossRef Giorgi L, Asgharian A, Hunter B. Ropinirole in patients with restless legs syndrome and baseline IRLS total scores ≥ 24: efficacy and tolerability in a 26-week, double-blind, parallel-group, placebo-controlled study followed by a 40-week open-label extension. Clin Ther. 2013; 35(9):1321-36.PubMedCrossRef
113.
Zurück zum Zitat Zhang J, Liu B, Zheng Y, Chu T, Yang Z. Pramipexole for Chinese people with primary restless legs syndrome: a 12-week multicenter, randomized, double-blind study. Sleep Med 2015;16:181–185.PubMedCrossRef Zhang J, Liu B, Zheng Y, Chu T, Yang Z. Pramipexole for Chinese people with primary restless legs syndrome: a 12-week multicenter, randomized, double-blind study. Sleep Med 2015;16:181–185.PubMedCrossRef
114.
Zurück zum Zitat Ferini-Strambi L, Aarskog D, Partinen M, et al. Effect of pramipexole on RLS symptoms and sleep: a randomized, double-blind, placebo-controlled trial. Sleep Med 2008;9:874–881.PubMedCrossRef Ferini-Strambi L, Aarskog D, Partinen M, et al. Effect of pramipexole on RLS symptoms and sleep: a randomized, double-blind, placebo-controlled trial. Sleep Med 2008;9:874–881.PubMedCrossRef
115.
Zurück zum Zitat Hening WA, Allen RP, Ondo WG, et al. Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States. Mov Disord 2010;25:1675–1683.PubMedCrossRef Hening WA, Allen RP, Ondo WG, et al. Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States. Mov Disord 2010;25:1675–1683.PubMedCrossRef
116.
Zurück zum Zitat Inoue Y, Shimizu T, Hirata K, et al. Efficacy and safety of rotigotine in Japanese patients with restless legs syndrome: a phase 3, multicenter, randomized, placebo-controlled, double-blind, parallel-group study. Sleep Med 2013;14:1085–1091.PubMedCrossRef Inoue Y, Shimizu T, Hirata K, et al. Efficacy and safety of rotigotine in Japanese patients with restless legs syndrome: a phase 3, multicenter, randomized, placebo-controlled, double-blind, parallel-group study. Sleep Med 2013;14:1085–1091.PubMedCrossRef
117.
Zurück zum Zitat Benes H, Kurella B, Kummer J, Kazenwadel J, Selzer R, Kohnen R. Rapid onset of action of levodopa in restless legs syndrome: a double-blind, randomized, multicenter, crossover trial. Sleep 1999;22:1073–1081.PubMedCrossRef Benes H, Kurella B, Kummer J, Kazenwadel J, Selzer R, Kohnen R. Rapid onset of action of levodopa in restless legs syndrome: a double-blind, randomized, multicenter, crossover trial. Sleep 1999;22:1073–1081.PubMedCrossRef
118.
Zurück zum Zitat Scholz H, Trenkwalder C, Kohnen R, Riemann D, Kriston L, Hornyak M. Levodopa for restless legs syndrome. Cochrane Database Syst Rev. 2011;(2):CD005504. Scholz H, Trenkwalder C, Kohnen R, Riemann D, Kriston L, Hornyak M. Levodopa for restless legs syndrome. Cochrane Database Syst Rev. 2011;(2):CD005504.
119.
Zurück zum Zitat García-Borreguero D. Dopaminergic Augmentation in Restless Legs Syndrome/Willis-Ekbom Disease: Identification and Management. Sleep Med Clin. 2015;10(3):287-92, xiii.PubMedCrossRef García-Borreguero D. Dopaminergic Augmentation in Restless Legs Syndrome/Willis-Ekbom Disease: Identification and Management. Sleep Med Clin. 2015;10(3):287-92, xiii.PubMedCrossRef
120.
Zurück zum Zitat Trenkwalder C, Winkelmann J, Inoue Y, Paulus W. Restless legs syndrome-current therapies and management of augmentation. Nat Rev Neurol. 2015;11(8):434-45.PubMedCrossRef Trenkwalder C, Winkelmann J, Inoue Y, Paulus W. Restless legs syndrome-current therapies and management of augmentation. Nat Rev Neurol. 2015;11(8):434-45.PubMedCrossRef
121.
Zurück zum Zitat Trenkwalder C, Allen R, Högl B, et al. Comorbidities, treatment, and pathophysiology in restless legs syndrome. Lancet Neurol. 2018;17(11):994-1005.PubMedCrossRef Trenkwalder C, Allen R, Högl B, et al. Comorbidities, treatment, and pathophysiology in restless legs syndrome. Lancet Neurol. 2018;17(11):994-1005.PubMedCrossRef
122.
Zurück zum Zitat Geyer J, Bogan R. Identification and treatment of augmentation in patients with restless legs syndrome: practical recommendations. Postgrad Med. 2017;129(7):667-675.PubMedCrossRef Geyer J, Bogan R. Identification and treatment of augmentation in patients with restless legs syndrome: practical recommendations. Postgrad Med. 2017;129(7):667-675.PubMedCrossRef
123.
Zurück zum Zitat Garcia-Borreguero D, Cano-Pumarega I, Garcia Malo C, Cruz Velarde JA, Granizo JJ, Wanner V. Reduced response to gabapentin enacarbil in restless legs syndrome following long-term dopaminergic treatment. Sleep Med. 2019;55:74-80.PubMedCrossRef Garcia-Borreguero D, Cano-Pumarega I, Garcia Malo C, Cruz Velarde JA, Granizo JJ, Wanner V. Reduced response to gabapentin enacarbil in restless legs syndrome following long-term dopaminergic treatment. Sleep Med. 2019;55:74-80.PubMedCrossRef
124.
Zurück zum Zitat Heim B, Djamshidian A, Heidbreder A, et al. Augmentation and impulsive behaviors in restless legs syndrome: Coexistence or association? Neurology. 2016;87(1):36-40.PubMedCrossRef Heim B, Djamshidian A, Heidbreder A, et al. Augmentation and impulsive behaviors in restless legs syndrome: Coexistence or association? Neurology. 2016;87(1):36-40.PubMedCrossRef
125.
Zurück zum Zitat Gatto EM, Aldinio V. Impulse Control Disorders in Parkinson’s Disease. A Brief and Comprehensive Review. Front Neurol. 2019;10:351.PubMedCrossRef Gatto EM, Aldinio V. Impulse Control Disorders in Parkinson’s Disease. A Brief and Comprehensive Review. Front Neurol. 2019;10:351.PubMedCrossRef
126.
Zurück zum Zitat Winkelmann J, Allen RP, Högl B, et al. Treatment of restless legs syndrome: Evidence-based review and implications for clinical practice (Revised 2017)§. Mov Disord. 2018;33(7):1077-1091.PubMedCrossRef Winkelmann J, Allen RP, Högl B, et al. Treatment of restless legs syndrome: Evidence-based review and implications for clinical practice (Revised 2017)§. Mov Disord. 2018;33(7):1077-1091.PubMedCrossRef
127.
Zurück zum Zitat VanMeter SA, Kavanagh ST, Warren S, Barrett RW. Dose response of Gabapentin Enacarbil versus placebo in subjects with moderate-to-severe primary restless legs syndrome: an integrated analysis of three 12-week studies. CNS Drugs. 2012;26(9):773-80.PubMedCrossRef VanMeter SA, Kavanagh ST, Warren S, Barrett RW. Dose response of Gabapentin Enacarbil versus placebo in subjects with moderate-to-severe primary restless legs syndrome: an integrated analysis of three 12-week studies. CNS Drugs. 2012;26(9):773-80.PubMedCrossRef
128.
Zurück zum Zitat Allen RP, Chen C, Garcia-Borreguero D, et al. Comparison of pregabalin with pramipexole for restless legs syndrome. N Engl J Med. 2014;370(7):621-31.PubMedCrossRef Allen RP, Chen C, Garcia-Borreguero D, et al. Comparison of pregabalin with pramipexole for restless legs syndrome. N Engl J Med. 2014;370(7):621-31.PubMedCrossRef
129.
Zurück zum Zitat Trenkwalder C, Beneš H, Grote L, et al. Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. Lancet Neurol. 2013;12(12):1141-50.PubMedCrossRef Trenkwalder C, Beneš H, Grote L, et al. Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. Lancet Neurol. 2013;12(12):1141-50.PubMedCrossRef
130.
Zurück zum Zitat Marques A, Fantini ML, Morand D, et al. Emergence of restless legs syndrome after subthalamic stimulation in Parkinson’s disease: a dopaminergic overstimulation? Sleep Med. 2015;16(5):583-8.PubMedCrossRef Marques A, Fantini ML, Morand D, et al. Emergence of restless legs syndrome after subthalamic stimulation in Parkinson’s disease: a dopaminergic overstimulation? Sleep Med. 2015;16(5):583-8.PubMedCrossRef
131.
Zurück zum Zitat Klepitskaya O, Liu Y, Sharma S, Sillau SH, Tsai J, Walters AS. Deep brain stimulation improves restless legs syndrome in patients with Parkinson disease. Neurology. 2018;91(11):e1013-e1021.PubMedCrossRef Klepitskaya O, Liu Y, Sharma S, Sillau SH, Tsai J, Walters AS. Deep brain stimulation improves restless legs syndrome in patients with Parkinson disease. Neurology. 2018;91(11):e1013-e1021.PubMedCrossRef
132.
Zurück zum Zitat Yoo SW, Kim JS, Oh YS, Ryu DW, Lee KS. Excessive daytime sleepiness and its impact on quality of life in de novo Parkinson’s disease. Neurol Sci. 2019;40(6):1151-1156.PubMedCrossRef Yoo SW, Kim JS, Oh YS, Ryu DW, Lee KS. Excessive daytime sleepiness and its impact on quality of life in de novo Parkinson’s disease. Neurol Sci. 2019;40(6):1151-1156.PubMedCrossRef
133.
Zurück zum Zitat Amara AW, Chahine LM, Caspell-Garcia C, et al. Longitudinal assessment of excessive daytime sleepiness in early Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2017;88(8):653-662.PubMedPubMedCentralCrossRef Amara AW, Chahine LM, Caspell-Garcia C, et al. Longitudinal assessment of excessive daytime sleepiness in early Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2017;88(8):653-662.PubMedPubMedCentralCrossRef
134.
Zurück zum Zitat Suzuki K, Okuma Y, Uchiyama T, et al. Impact of sleep-related symptoms on clinical motor subtypes and disability in Parkinson’s disease: a multicentre cross-sectional study. J Neurol Neurosurg Psychiatry. 2017;88(11):953-959.PubMedPubMedCentralCrossRef Suzuki K, Okuma Y, Uchiyama T, et al. Impact of sleep-related symptoms on clinical motor subtypes and disability in Parkinson’s disease: a multicentre cross-sectional study. J Neurol Neurosurg Psychiatry. 2017;88(11):953-959.PubMedPubMedCentralCrossRef
135.
Zurück zum Zitat Zhu K, van Hilten JJ, Marinus J. Course and risk factors for excessive daytime sleepiness in Parkinson’s disease. Parkinsonism Relat Disord. 2016;24:34-40.PubMedCrossRef Zhu K, van Hilten JJ, Marinus J. Course and risk factors for excessive daytime sleepiness in Parkinson’s disease. Parkinsonism Relat Disord. 2016;24:34-40.PubMedCrossRef
136.
Zurück zum Zitat Liguori C, Mercuri NB, Albanese M, Olivola E, Stefani A, Pierantozzi M. Daytime sleepiness may be an independent symptom unrelated to sleep quality in Parkinson’s disease. J Neurol. 2019;266(3):636-641.PubMedCrossRef Liguori C, Mercuri NB, Albanese M, Olivola E, Stefani A, Pierantozzi M. Daytime sleepiness may be an independent symptom unrelated to sleep quality in Parkinson’s disease. J Neurol. 2019;266(3):636-641.PubMedCrossRef
137.
Zurück zum Zitat Wen MC, Chan LL, Tan LCS, Tan EK. Mood and neural correlates of excessive daytime sleepiness in Parkinson’s disease. Acta Neurol Scand. 2017;136(2):84-96.PubMedCrossRef Wen MC, Chan LL, Tan LCS, Tan EK. Mood and neural correlates of excessive daytime sleepiness in Parkinson’s disease. Acta Neurol Scand. 2017;136(2):84-96.PubMedCrossRef
138.
Zurück zum Zitat Simuni T, Caspell-Garcia C, Coffey C, et al. Correlates of excessive daytime sleepiness in de novo Parkinson’s disease: A case control study. Mov Disord. 2015;30(10):1371-81.PubMedPubMedCentralCrossRef Simuni T, Caspell-Garcia C, Coffey C, et al. Correlates of excessive daytime sleepiness in de novo Parkinson’s disease: A case control study. Mov Disord. 2015;30(10):1371-81.PubMedPubMedCentralCrossRef
139.
Zurück zum Zitat Yousaf T, Pagano G, Niccolini F, Politis M. Excessive daytime sleepiness may be associated with caudate denervation in Parkinson disease. J Neurol Sci. 2018;387:220-227.PubMedCrossRef Yousaf T, Pagano G, Niccolini F, Politis M. Excessive daytime sleepiness may be associated with caudate denervation in Parkinson disease. J Neurol Sci. 2018;387:220-227.PubMedCrossRef
140.
Zurück zum Zitat Spindler M, Gooneratne NS, Siderowf A, Duda JE, Cantor C, Dahodwala N. Daytime sleepiness is associated with falls in Parkinson’s disease. J Parkinsons Dis. 2013;3(3):387-91.PubMedPubMedCentralCrossRef Spindler M, Gooneratne NS, Siderowf A, Duda JE, Cantor C, Dahodwala N. Daytime sleepiness is associated with falls in Parkinson’s disease. J Parkinsons Dis. 2013;3(3):387-91.PubMedPubMedCentralCrossRef
141.
Zurück zum Zitat Videnovic A, Klerman EB, Wang W, Marconi A, Kuhta T, Zee PC. Timed Light Therapy for Sleep and Daytime Sleepiness Associated With Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2017; 74(4):411-418.PubMedPubMedCentralCrossRef Videnovic A, Klerman EB, Wang W, Marconi A, Kuhta T, Zee PC. Timed Light Therapy for Sleep and Daytime Sleepiness Associated With Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2017; 74(4):411-418.PubMedPubMedCentralCrossRef
142.
143.
Zurück zum Zitat Högl B, Saletu M, Brandauer E, et al. Modafinil for the treatment of daytime sleepiness in Parkinson’s disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep. 2002;25(8):905-9.PubMedCrossRef Högl B, Saletu M, Brandauer E, et al. Modafinil for the treatment of daytime sleepiness in Parkinson’s disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep. 2002;25(8):905-9.PubMedCrossRef
144.
Zurück zum Zitat Adler CH, Caviness JN, Hentz JG, Lind M, Tiede J. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson’s disease. Mov Disord. 2003;18(3):287-93.PubMedCrossRef Adler CH, Caviness JN, Hentz JG, Lind M, Tiede J. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson’s disease. Mov Disord. 2003;18(3):287-93.PubMedCrossRef
145.
Zurück zum Zitat Ondo WG, Fayle R, Atassi F, Jankovic J. Modafinail for daytime somnolence in Parkinson’s disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry. 2005;76(12):1636-9.PubMedPubMedCentralCrossRef Ondo WG, Fayle R, Atassi F, Jankovic J. Modafinail for daytime somnolence in Parkinson’s disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry. 2005;76(12):1636-9.PubMedPubMedCentralCrossRef
146.
Zurück zum Zitat Büchele F, Hackius M, Schreglmann SR, et al. Sodium Oxybate for Excessive Daytime Sleepiness and Sleep Disturbance in Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2018;75(1):114-118.PubMedCrossRef Büchele F, Hackius M, Schreglmann SR, et al. Sodium Oxybate for Excessive Daytime Sleepiness and Sleep Disturbance in Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2018;75(1):114-118.PubMedCrossRef
147.
Zurück zum Zitat Suzuki K, Miyamoto M, Miyamoto T, et al. Istradefylline improves daytime sleepiness in patients with Parkinson’s disease: An open-label, 3-month study. J Neurol Sci. 2017;380:230-233.PubMedCrossRef Suzuki K, Miyamoto M, Miyamoto T, et al. Istradefylline improves daytime sleepiness in patients with Parkinson’s disease: An open-label, 3-month study. J Neurol Sci. 2017;380:230-233.PubMedCrossRef
148.
Zurück zum Zitat Rye DB. Excessive daytime sleepiness and unintended sleep in Parkinson’s disease. Curr Neurol Neurosci Rep. 2006;6(2):169-76.PubMedCrossRef Rye DB. Excessive daytime sleepiness and unintended sleep in Parkinson’s disease. Curr Neurol Neurosci Rep. 2006;6(2):169-76.PubMedCrossRef
149.
Zurück zum Zitat Crosta F, Desideri G, Marini C. Obstructive sleep apnea syndrome in Parkinson’s disease and other parkinsonisms. Funct Neurol. 2017;32(3):137-141.PubMedPubMedCentralCrossRef Crosta F, Desideri G, Marini C. Obstructive sleep apnea syndrome in Parkinson’s disease and other parkinsonisms. Funct Neurol. 2017;32(3):137-141.PubMedPubMedCentralCrossRef
150.
151.
Zurück zum Zitat Cochen De Cock V, Benard-Serre N, Driss V, et al. Supine sleep and obstructive sleep apnea syndrome in Parkinson’s disease. Sleep Med. 2015;16(12):1497-501.PubMedCrossRef Cochen De Cock V, Benard-Serre N, Driss V, et al. Supine sleep and obstructive sleep apnea syndrome in Parkinson’s disease. Sleep Med. 2015;16(12):1497-501.PubMedCrossRef
152.
Zurück zum Zitat Huang JY, Zhang JR, Shen Y, et al. Effect of Rapid Eye Movement Sleep Behavior Disorder on Obstructive Sleep Apnea Severity and Cognition of Parkinson’s Disease Patients. Chin Med J (Engl). 2018;131(8):899-906.PubMedPubMedCentralCrossRef Huang JY, Zhang JR, Shen Y, et al. Effect of Rapid Eye Movement Sleep Behavior Disorder on Obstructive Sleep Apnea Severity and Cognition of Parkinson’s Disease Patients. Chin Med J (Engl). 2018;131(8):899-906.PubMedPubMedCentralCrossRef
153.
Zurück zum Zitat Kaminska M, Lafontaine AL, Kimoff RJ. The Interaction between Obstructive Sleep Apnea and Parkinson’s Disease: Possible Mechanisms and Implications for Cognitive Function. Parkinsons Dis. 2015;2015:849472.PubMedPubMedCentral Kaminska M, Lafontaine AL, Kimoff RJ. The Interaction between Obstructive Sleep Apnea and Parkinson’s Disease: Possible Mechanisms and Implications for Cognitive Function. Parkinsons Dis. 2015;2015:849472.PubMedPubMedCentral
154.
Zurück zum Zitat Béland SG, Postuma RB, Latreille V, et al. Observational Study of the Relation between Parkinson’s Disease and Sleep Apnea. J Parkinsons Dis. 2015;5(4):805-11.PubMedCrossRef Béland SG, Postuma RB, Latreille V, et al. Observational Study of the Relation between Parkinson’s Disease and Sleep Apnea. J Parkinsons Dis. 2015;5(4):805-11.PubMedCrossRef
155.
156.
Zurück zum Zitat Mery VP, Gros P, Lafontaine AL, Robinson A, Benedetti A, Kimoff RJ, Kaminska M. Reduced cognitive function in patients with Parkinson disease and obstructive sleep apnea. Neurology. 2017;88(12):1120-1128.PubMedCrossRef Mery VP, Gros P, Lafontaine AL, Robinson A, Benedetti A, Kimoff RJ, Kaminska M. Reduced cognitive function in patients with Parkinson disease and obstructive sleep apnea. Neurology. 2017;88(12):1120-1128.PubMedCrossRef
157.
Zurück zum Zitat Neikrug AB, Liu L, Avanzino JA, et al. Continuous positive airway pressure improves sleep and daytime sleepiness in patients with Parkinson disease and sleep apnea. Sleep. 2014;37(1):177-85.PubMedPubMedCentralCrossRef Neikrug AB, Liu L, Avanzino JA, et al. Continuous positive airway pressure improves sleep and daytime sleepiness in patients with Parkinson disease and sleep apnea. Sleep. 2014;37(1):177-85.PubMedPubMedCentralCrossRef
158.
Zurück zum Zitat Terzaghi M, Spelta L, Minafra B, et al. Treating sleep apnea in Parkinson’s disease with C-PAP: feasibility concerns and effects on cognition and alertness. Sleep Med. 2017;33:114-118.PubMedCrossRef Terzaghi M, Spelta L, Minafra B, et al. Treating sleep apnea in Parkinson’s disease with C-PAP: feasibility concerns and effects on cognition and alertness. Sleep Med. 2017;33:114-118.PubMedCrossRef
159.
Zurück zum Zitat De Pablo-Fernández E, Courtney R, Warner TT, Holton JL. A Histologic Study of the Circadian System in Parkinson Disease, Multiple System Atrophy, and Progressive Supranuclear Palsy. JAMA Neurol. 2018;75(8):1008-1012.PubMedPubMedCentralCrossRef De Pablo-Fernández E, Courtney R, Warner TT, Holton JL. A Histologic Study of the Circadian System in Parkinson Disease, Multiple System Atrophy, and Progressive Supranuclear Palsy. JAMA Neurol. 2018;75(8):1008-1012.PubMedPubMedCentralCrossRef
160.
Zurück zum Zitat Ortuño-Lizarán I, Esquiva G, Beach TG, et al. Degeneration of human photosensitive retinal ganglion cells may explain sleep and circadian rhythms disorders in Parkinson’s disease. Acta Neuropathol Commun. 2018;6(1):90.PubMedPubMedCentralCrossRef Ortuño-Lizarán I, Esquiva G, Beach TG, et al. Degeneration of human photosensitive retinal ganglion cells may explain sleep and circadian rhythms disorders in Parkinson’s disease. Acta Neuropathol Commun. 2018;6(1):90.PubMedPubMedCentralCrossRef
161.
Zurück zum Zitat Speelman AD, van de Warrenburg BP, van Nimwegen M, Petzinger GM, Munneke M, Bloem BR. How might physical activity benefit patients with Parkinson disease? Nat Rev Neurol. 2011;7(9):528-34.PubMedCrossRef Speelman AD, van de Warrenburg BP, van Nimwegen M, Petzinger GM, Munneke M, Bloem BR. How might physical activity benefit patients with Parkinson disease? Nat Rev Neurol. 2011;7(9):528-34.PubMedCrossRef
162.
Zurück zum Zitat Videnovic A, Noble C, Reid KJ, et al. Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson disease. JAMA Neurol. 2014;71(4):463-9.PubMedPubMedCentralCrossRef Videnovic A, Noble C, Reid KJ, et al. Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson disease. JAMA Neurol. 2014;71(4):463-9.PubMedPubMedCentralCrossRef
163.
164.
Zurück zum Zitat Willis GL, Turner EJ. Primary and secondary features of Parkinson’s disease improve with strategic exposure to bright light: a case series study. Chronobiol Int. 2007;24(3):521-37.PubMedCrossRef Willis GL, Turner EJ. Primary and secondary features of Parkinson’s disease improve with strategic exposure to bright light: a case series study. Chronobiol Int. 2007;24(3):521-37.PubMedCrossRef
Metadaten
Titel
Sleep Issues in Parkinson’s Disease and Their Management
verfasst von
José Rafael P. Zuzuárregui
Emmanuel H. During
Publikationsdatum
01.10.2020
Verlag
Springer International Publishing
Erschienen in
Neurotherapeutics / Ausgabe 4/2020
Print ISSN: 1933-7213
Elektronische ISSN: 1878-7479
DOI
https://doi.org/10.1007/s13311-020-00938-y

Weitere Artikel der Ausgabe 4/2020

Neurotherapeutics 4/2020 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.